The incidence of treatment-related ALT and AST increases, respectively, was reported in 9% and 6% of patients treated with axitinib monotherapy, in 13% and 11% of patients treated with axitinib/avelumab and in 24% and 23% of patients treated with combinations of axitinib/pembrolizumab (Supplementary Table S3).2,13,14 The FDA label of the combinations axitinib/avelumab and axitinib/pembrolizumab includes special warnings for hepatic toxicity and hepatitis.30,31. Here, GPT is linked to hepatitis A virus infection.